A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Hepatitis B / Hepatitis D Co-infection

Trial Profile

A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Hepatitis B / Hepatitis D Co-infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; REP 2139-Ca (Primary)
  • Indications Hepatitis B; Hepatitis D
  • Focus Adverse reactions; Proof of concept
  • Sponsors REPLICor
  • Most Recent Events

    • 20 Apr 2017 Results published in a Replicor media release.
    • 20 Apr 2017 According to a Replicor media release, results from this trial were presented at the European Association for the Study of the Liver (EASL) 2017 annual meeting.
    • 06 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top